Alyeska Investment Group
HAE icon

Alyeska Investment Group’s Haemonetics HAE Stock Holding History

Alyeska Investment Group’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-85,304
Closed -$10.8M – 443
2019
Q3 		$10.8M Buy
+85,304
New +$10.8M 0.16% 163

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Alyeska Investment Group's HAE Position: Q4 2019 in Review

Alyeska Investment Group sold out of Haemonetics (HAE) in Q4 2019, closing a stake of 85,304 shares — an estimated $10.8M sold.

Alyeska Investment Group first reported a position in HAE in Q3 2019 and held it in 1 quarter. The position peaked at $10.8M in Q3 2019. 298 funds tracked by Wall St. Rank hold HAE as of Q4 2019.

  • Alyeska Investment Group reported no remaining Haemonetics position as of Q4 2019 after selling out during the quarter.
  • Alyeska Investment Group sold 85,304 Haemonetics shares in Q4 2019, an estimated $10.8M.
  • Alyeska Investment Group first reported a position in Haemonetics in Q3 2019 and held it in 1 quarter.
  • Alyeska Investment Group's Haemonetics position peaked at $10.8M in Q3 2019.
  • 298 funds tracked by Wall St. Rank held Haemonetics as of Q4 2019.

Based on Alyeska Investment Group's 13F filing for Q4 2019, filed 14 Feb 2020.